The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Glorion     3-ethyl-4-methyl-N-[2-[4- [(4...

Synonyms: Amarel, Amaryl, Endial, GLIMPERIDE, Glemax, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of glimepiride


Psychiatry related information on glimepiride


High impact information on glimepiride


Chemical compound and disease context of glimepiride


Biological context of glimepiride


Anatomical context of glimepiride


Associations of glimepiride with other chemical compounds


Gene context of glimepiride


Analytical, diagnostic and therapeutic context of glimepiride


  1. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Rosenkranz, B., Profozic, V., Metelko, Z., Mrzljak, V., Lange, C., Malerczyk, V. Diabetologia (1996) [Pubmed]
  2. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Martin, S., Kolb, H., Beuth, J., van Leendert, R., Schneider, B., Scherbaum, W.A. Diabetologia (2003) [Pubmed]
  3. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Niemi, M., Backman, J.T., Neuvonen, M., Laitila, J., Neuvonen, P.J., Kivistö, K.T. Clin. Pharmacol. Ther. (2001) [Pubmed]
  4. The sulfonylurea glimepiride regulates intracellular routing of the insulin-receptor complexes through their interaction with specific protein kinase C isoforms. Hribal, M.L., D'Alfonso, R., Giovannone, B., Lauro, D., Liu, Y.Y., Borboni, P., Federici, M., Lauro, R., Sesti, G. Mol. Pharmacol. (2001) [Pubmed]
  5. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Charpentier, G., Fleury, F., Dubroca, I., Vaur, L., Clerson, P. Diabetes Metab. (2005) [Pubmed]
  6. Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport. Müller, G., Dearey, E.A., Korndörfer, A., Bandlow, W. J. Cell Biol. (1994) [Pubmed]
  7. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. Fukuen, S., Iwaki, M., Yasui, A., Makishima, M., Matsuda, M., Shimomura, I. J. Biol. Chem. (2005) [Pubmed]
  8. Impairment of myocardial protection in type 2 diabetic patients. Lee, T.M., Chou, T.F. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  9. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Müller, G. Mol. Med. (2000) [Pubmed]
  10. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Luis Bautista, J., Bugos, C., Dirnberger, G., Atherton, T. Clinical therapeutics. (2003) [Pubmed]
  11. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Kim, H.J., Kang, E.S., Kim, D.J., Kim, S.H., Ahn, C.W., Cha, B.S., Nam, M., Chung, C.H., Lee, K.W., Nam, C.M., Lee, H.C. Clin. Endocrinol. (Oxf) (2007) [Pubmed]
  12. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Tan, M., Johns, D., González Gálvez, G., Antúnez, O., Fabián, G., Flores-Lozano, F., Zúñiga Guajardo, S., Garza, E., Morales, H., Konkoy, C., Herz, M. Clinical therapeutics. (2004) [Pubmed]
  13. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Müller, G., Wied, S. Diabetes (1993) [Pubmed]
  14. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Tsunekawa, T., Hayashi, T., Suzuki, Y., Matsui-Hirai, H., Kano, H., Fukatsu, A., Nomura, N., Miyazaki, A., Iguchi, A. Diabetes Care (2003) [Pubmed]
  15. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Niemi, M., Cascorbi, I., Timm, R., Kroemer, H.K., Neuvonen, P.J., Kivistö, K.T. Clin. Pharmacol. Ther. (2002) [Pubmed]
  16. Sulfonylurea stimulation of insulin secretion. Proks, P., Reimann, F., Green, N., Gribble, F., Ashcroft, F. Diabetes (2002) [Pubmed]
  17. Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide. Haupt, A., Kausch, C., Dahl, D., Bachmann, O., Stumvoll, M., Häring, H.U., Matthaei, S. Diabetes Care (2002) [Pubmed]
  18. The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3T3 adipocytes. Müller, G., Dearey, E.A., Pünter, J. Biochem. J. (1993) [Pubmed]
  19. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Ueba, H., Kuroki, M., Hashimoto, S., Umemoto, T., Yasu, T., Ishikawa, S.E., Saito, M., Kawakami, M. Atherosclerosis (2005) [Pubmed]
  20. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Ovalle, F., Bell, D.S. Diabetes Care (2004) [Pubmed]
  21. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Niemi, M., Neuvonen, P.J., Kivistö, K.T. Clin. Pharmacol. Ther. (2001) [Pubmed]
  22. Cholesterol depletion blocks redistribution of lipid raft components and insulin-mimetic signaling by glimepiride and phosphoinositolglycans in rat adipocytes. Müller, G., Hanekop, N., Wied, S., Frick, W. Mol. Med. (2002) [Pubmed]
  23. Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Inukai, K., Watanabe, M., Nakashima, Y., Takata, N., Isoyama, A., Sawa, T., Kurihara, S., Awata, T., Katayama, S. Biochem. Biophys. Res. Commun. (2005) [Pubmed]
  24. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Gribble, F.M., Ashcroft, F.M. Metab. Clin. Exp. (2000) [Pubmed]
  25. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Bijlstra, P.J., Lutterman, J.A., Russel, F.G., Thien, T., Smits, P. Diabetologia (1996) [Pubmed]
  26. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Klepzig, H., Kober, G., Matter, C., Luus, H., Schneider, H., Boedeker, K.H., Kiowski, W., Amann, F.W., Gruber, D., Harris, S., Burger, W. Eur. Heart J. (1999) [Pubmed]
WikiGenes - Universities